A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q - Fenaux, P; Giagounidis, A; Selleslag, D (Blood, 2011)
et al.